Effect of Mirabegron on brown adipose tissue
- Conditions
- Obesity and dyslipidemiaTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- EUCTR2016-000237-48-NL
- Lead Sponsor
- eiden University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 20
• Male volunteers. 10 white Caucasians, born in the Netherlands. 10 South Asians, living in the Netherlands.
• Age: 18-30 years
• BMI = 25 kg/m2
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
•BMI > 25 kg/m2
•Recent excessive weight loss or exercise
•Alcohol and/ or drugs abuse
•Excessieve smoking (>10 cigarettes/day)
•Any significant chronic disease, including diabetes, Renal, hepatic or endocrine disease
•Heart disease or arrhythmias
•Thyroid disease or thyroid medication
•Hypertension
•Use of medication known to influence glucose and/or lipid metabolism or BAT activity (e.g. beta blockers or calcium channel blockers)
•Use of drugs that influence cardiac function or affect QT time
•Use of MAO inhibitor
•Use of systemic corticosteroids in previous six weeks
•Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
•Contraindications for undergoing an MRI scan.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method